IVF INVO Fertility, Inc.

MIXED Impact: 5/10 PRESS-RELEASE
Horizon weeks Filed Jun 2, 2026 Processed 3d 9h ago Wire GlobeNewswire
Press release: earnings
Latest settled — T+1d ⚠ clustered
IVF ▲ +11.84% at T+1d
NEUTRAL call ✓ call won +11.84% · α vs SPY +12.54% · entry $1.52 → $1.70
Next anchor: T+5d in 4d
Currently $1.59 · +4.61% from $1.52 entry
Entry anchored
Jun 2, 05:35 AM ET
via Databento tick
T+1d
+11.84%
call +11.84% · α +12.54%
$1.70
settled 2d ago
T+5d
call — · α —
in 4d
T+20d
call — · α —
in 26d
T+60d
call — · α —
in 3mo

Price Chart

Loading chart...

Executive Summary

INVO Fertility reported FY2025 revenue of $6.84M (+5% YoY) and a net loss from continuing operations of $(5.3)M, improving from $(7.7)M in FY2024. The company highlighted a strengthened balance sheet after $11.5M in financing, the acquisition of Family Beginnings, and conversion of all Series C-2 Preferred Stock, but adjusted EBITDA worsened to $(3.2)M from $(2.2)M. Despite operational progress, the stock remains highly speculative with a $2M market cap and negative historical returns on prior calls.

Actionable Insight

The improved loss profile and balance sheet strengthening are positive, but worsening adjusted EBITDA and heavy dilution (shares outstanding surged from ~2,500 to ~1.8M) cap the upside. Monitor Q1 2026 results for organic growth traction and integration of Family Beginnings; the stock's micro-cap status and poor historical T+20 performance suggest high risk.

Key Facts

  • FY2025 revenue $6.84M, +5% YoY from $6.53M
  • Net loss from continuing operations improved to $(5.3)M from $(7.7)M
  • Adjusted EBITDA worsened to $(3.2)M from $(2.2)M
  • Completed $11.5M in financing (Dec 2025/Jan 2026) and acquired Family Beginnings clinic
  • All Series C-2 Preferred Stock converted or retired; common shares outstanding ~1.8M as of June 2, 2026
  • EPS from continuing operations: $(45.57) basic/diluted (FY2025) vs $(3,078.74) in FY2024 (driven by massive share count increase from 2,514 to 117,083 weighted avg shares)

Financial Impact

Revenue growth of ~$309K (+5%) YoY; net loss improved by ~$2.4M; adjusted EBITDA declined by ~$925K; EPS improved from $(3,078.74) to $(45.57) due to share dilution

revenuenet lossadjusted EBITDAEPSdebt

Risk Factors

  • Adjusted EBITDA deterioration despite revenue growth
  • Massive share dilution (weighted avg shares from 2,514 to 117,083) obscures true per-share improvement
  • Micro-cap ($2M market cap) with low liquidity and negative historical returns on prior analyst calls
  • Reliance on continued financing and acquisition pipeline for growth

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
80% bullish (5 analysts)

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3305182
6 reports for IVF
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for IVF — sortable, filterable
Type Now
Jun 2, 2026
3d ago
Press Release
BEARISH ★ 6/10
awaiting T+1
Jun 2, 2026
3d ago
8-K
MIXED ★ 5/10
$1.52 $1.70▲ +11.84%▲ +12.54%$1.59 (+4.61%)
Jun 2, 2026
3d ago
8-K
BEARISH ★ 8/10
$1.52 $1.70▼ −11.84%▼ −12.54%$1.59 (−4.61%)
Jun 2, 2026
3d ago
Press Release
MIXED ★ 5/10
$1.52 $1.70▲ +11.84%▲ +12.54%$1.59 (+4.61%)
Mar 3, 2026
13w ago
Press Release
NEUTRAL ★ 4/10
$4.33 $4.44▲ +2.54%▲ +1.78%$1.59 (−63.24%)
Feb 24, 2026
14w ago
8-K
BULLISH ★ 8/10
$5.00 $4.97▼ −0.50%▼ −1.33%$1.59 (−68.17%)
Showing 6 of 6

US Market Status

Market Closed — Opens Mon (39h 14m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access